The proposed EU PFAS restriction is not yet final, but it is already reshaping due diligence for fluorinated pharmaceutical intermediates. Learn what suppliers and buyers should map across structures, process materials, equipment, documentation and change control.
AI can screen chemical records for isomer-related inconsistencies, but batch identity, stereochemical purity and biological performance still require analytical evidence.
Chemical purity alone cannot establish the quality of a chiral pharmaceutical intermediate. Learn how route design, stereoselective analysis, specifications, documentation and change control help preserve stereochemical integrity.
Nitrosamine control is most effective when it begins before the final API or drug product. This article examines how raw materials, intermediates, reagents, recovered solvents, route design and change control shape risk.
A certificate of analysis is essential, but it is not the whole quality story. Learn what buyers should verify about identity, methods, impurities, traceability and change control when sourcing pharmaceutical intermediates.
Follow the path from an AI-designed molecule to route validation, impurity control, analytical release, scale-up and reliable supply.
AI is expanding chemical-space exploration. See why diverse, functionalized heterocyclic building blocks remain central to medicinal chemistry.
WAIC 2026 highlights AI drug discovery, protein design, medical agents and smart healthcare, while underscoring the need for scientific and clinical validation.
AI can support route search and prediction, but experimental judgment remains essential. Explore the future of AI–chemist collaboration.
AI can propose novel molecules faster than catalogs can supply them. Learn how custom synthesis bridges design, laboratory validation and scale.
See how AI drug discovery is changing pharmaceutical sourcing—and why route evaluation, specialized building blocks and responsive chemistry matter.